08622 HUAKANG BIOMED
- 0.090
- -0.002-2.17%
HUAKANG BIOMED News
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
華康生物醫學：2023年報
Huakang Biomedical (08622) completed placement of 31 million shares to raise approximately HK$2.96 million
Huakang Biomedical (08622) issued an announcement. The conditions for the placement have been met, and on April 2, 2024...
Huakang Biomedical (08622.HK) obtained Kokusai Resources Company Limited's additional common shares by 35.272 million shares worth approximately HK$4.317,300
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Kokusai Resources Company Limited increased its share holdings of $Huakang Biomedical (08622.HK) $35.272 million on March 26 with an average price of HK$0.1224 per share on the market and HK$0.121 per share outside the market, totaling HK$35.272 million, worth about HK$4.317,300. After the increase in holdings, Kokusai Resources Company Limited's latest shareholding number was 121 million shares, and the ratio of good positions was
Huakang Biomedical (08622.HK) received 12.728 million additional shares of common stock worth approximately HK$1,538,800 from Kokusai Resources Company Limited
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Kokusai Resources Company Limited increased its share holdings of $Huakang Biomedical (08622.HK) by $12.728 million at an average price of HK$0.1209 per share on March 25, worth approximately HK$1,538,800. After the increase in holdings, Kokusai Resources Company Limited's latest shareholding was 85.48 million shares, and the good position ratio rose from 16.59% to 18.21%. Honko
Huakang Biomedical (08622.HK): Chen Jiansheng Resigns as Independent Non-Executive Director
Huakang Biomedical (08622.HK) announced that Chen Jiansheng resigned as an independent non-executive director of the company, a member of the Audit Committee and Nomination Committee in order to invest more time in his personal business and other matters, effective April 2, 2024.
Huakang Biomedical (08622) announced 2023 results, net loss of 5.782 million yuan, an increase of 88% year-on-year
Huakang Biomedical (08622) announced its 2023 results, with revenue of 246.29 million yuan, a year-on-year decrease of 2.8...
華康生物醫學：截至二零二三年十二月三十一日止年度的年度業績公告
Huakang Biomedical (08622) Fa Ying Guang expects annual shareholders' losses to be no more than 5.8 million yuan
Huakang Biomedical (08622) issued an announcement that it is expected that the company owner's losses during the period will end in December 2023...
HUAKANG BIOMED: PROFIT WARNING
Huakang Biomedical (08622) completed the placement of a total of 31 million shares to raise approximately HK$3.18 million
Huakang Biomedical (08622) issued an announcement. The conditions for the placement have been met, and on March 2, 2024...
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Huakang Biomedical (08622) has signed a memorandum of understanding with respect to potential sales and distribution cooperation in China
According to Zhitong Finance App News, Huakang Biomedical (08622) announced that Huakang Hong Kong, a direct wholly-owned subsidiary of the company, signed a memorandum of understanding with Fujig after the trading session on February 20, 2024. The details include potential sales and distribution cooperation in China (including) selling and distributing the company's biological agents and immediate biomedical testing products on the platforms and channels of Fujig in China. Other than a few provisions (including due diligence, validity and exclusivity, confidentiality, and applicable law and jurisdiction), the MOU is not legally binding. The directors believe that if cooperation with pig saving is implemented, it will be
Huakang Biomedical (08622) plans to sell a maximum of 62 million new shares at a discount of approximately 13.51% to raise about HK$5.85 million
According to Zhitong Finance App, Huakang Biomedical (08622) issued an announcement. On February 9, 2024, the company signed a placement agreement with the placement agent. The placement agent agreed to do its best to place up to 62 million new shares to no less than six independent contractors at a price of HK$0.096 per share. The maximum number of shares to be placed was 62 million shares, accounting for approximately 12.39% of the company's total issued share capital expanded through placement transactions. Each share was placed at HK$0.096, and the GEM closing price was HK$0.111 per share at a discount of approximately 13.51% on February 9. bulletins
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Huakang Biomedical (08622.HK) obtained Kokusai Resources Company Limited's OTC share holdings of 7.528 million shares worth approximately HK$978,600
On February 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on February 5, Kokusai Resources Company Limited increased its OTC share holdings of $Huakang Biomedical (08622.HK) by $7,528 million at an average price of HK$0.13 per share, worth approximately HK$978,600. After the increase in holdings, Kokusai Resources Company Limited's latest shareholding was 72.752 million shares, and the good position ratio rose from 15.59% to 16.59%. Pictures come
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Huakang Biomedical (08622.HK) obtained Kokusai Resources Company Limited's OTC share holdings of 65.224 million shares worth approximately HK$3.202,500
On January 29, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 29, Kokusai Resources Company Limited increased its OTC share holdings of $Huakang Biomedical (08622.HK) by $65.224 million at an average price of HK$0.0491 per share on January 25, worth approximately HK$3.202,500. After the increase in holdings, Kokusai Resources Company Limited's latest shareholding number was 65.224 million shares, and the good position ratio increased from 0.00% to 15.5
Ever Charming Inc. sold 652,24,000 common shares of Huakang Biomedical (08622.HK) off the market, worth approximately HK$3.202,500
On January 26, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 26, Ever Charming Inc. sold $65.224 million common shares worth about HK$3.202,500 on January 25 at an average price of HK$0.0491 per share. After the sale, Ever Charming Inc.'s latest shareholding was 0 shares, and the good position ratio dropped from 15.59% to 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, large stocks
Analysis
Price Target
No Data
